All In Biotech

Drug Trial Radar · NCT07811999

Comparing the Extent to Which Romosozumab (AMG 785) is Made Available in the Body When Administered as a Single SC Injection or as 2 SC Injections

A Phase 1, Open-label, Randomized, Parallel Group Study to Evaluate the Relative Bioavailability of Romosozumab (AMG 785) 210 mg Administered as a Single SC Injection or 2 SC Injections in Healthy Participants

Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 308 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

308

Planned (sponsor's estimate)

Start

Sep 22, 2026

Primary completion

Jan 14, 2027

Study completion Jan 14, 2027

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Sep 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of this trial is to evaluate the relative bioavailability of romosozumab administered as a single 2.34 mL subcutaneous (SC) injection from a prefilled syringe (PFS) or 2 x 1.17 mL SC injections from PFS in healthy participants.

Conditions

  • Healthy Participants

Interventions

  • RomosozumabDrug

    Romosozumab will be administered via SC injection using a PFS.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUCinf) of romosozumabTime frame: Up to Day 85
  2. Area Under the Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUClast) of romosozumabTime frame: Up to Day 85
  3. Maximum Observed Serum Concentration (Cmax) of romosozumabTime frame: Up to Day 85

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • QPS Miami

    Miami, Florida · Recruiting

  • Fortrea Clinical Research Unit Limited - Leeds

    Leeds, LDS, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.